[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2310023T3 - Sammensætning, som omfatter ekstrakt af grøn te og ekstrakt af granatæble til anvendelse ved forebyggelse eller reduktion af progression af prostatacancer - Google Patents

Sammensætning, som omfatter ekstrakt af grøn te og ekstrakt af granatæble til anvendelse ved forebyggelse eller reduktion af progression af prostatacancer Download PDF

Info

Publication number
DK2310023T3
DK2310023T3 DK09781009.7T DK09781009T DK2310023T3 DK 2310023 T3 DK2310023 T3 DK 2310023T3 DK 09781009 T DK09781009 T DK 09781009T DK 2310023 T3 DK2310023 T3 DK 2310023T3
Authority
DK
Denmark
Prior art keywords
green tea
dose
prostate cancer
extract
composition
Prior art date
Application number
DK09781009.7T
Other languages
English (en)
Inventor
Franco Gaetani
Ashraf Virmani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK2310023T3 publication Critical patent/DK2310023T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (6)

1. Kombination af ekstrakt af grøn te og ekstrakt af granatæble til anvendelse til forebyggelse eller reduktion af progressionen af prostatacancer.
2. Kombination til anvendelse ifølge krav 1, hvilken kombination yderligere omfatter lycopen, selen, zink, savpalme, sojaisoflavon og L-carnitin.
3. Kombination til anvendelse ifølge krav 1 eller 2, i hvilken kombination ekstrakt af grøn te er til stede i en dosis fra 25 til 800 mg, ekstrakt af granatæble er til stede i en dosis fra 25 til 800 mg, lycopen er til stede i en dosis fra 0,03 til 30,0 mg, selen er til stede i en dosis fra 8,2 til 500 pg, zink er til stede i en dosis fra 1 til 200 mg, savpalme er til stede i en dosis fra 10 til 400 mg, sojaisoflavon er til stede i en dosis fra 10 til 500 mg, og L-carnitin er til stede i en dosis fra 50 til 500 mg.
4. Kombination til anvendelse ifølge krav 1 eller 2 som lægemiddel.
5. Kombination til anvendelse ifølge krav 1 eller 2 som kosttilskud.
6. Kombination til anvendelse ifølge krav 1 eller 2, hvilken kombination yderligere omfatter coenzymer, mineralstoffer, antioxidanter, vitaminer og midler, som er egnede til behandling af prostatacancer.
DK09781009.7T 2008-07-31 2009-07-24 Sammensætning, som omfatter ekstrakt af grøn te og ekstrakt af granatæble til anvendelse ved forebyggelse eller reduktion af progression af prostatacancer DK2310023T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161516 2008-07-31
PCT/EP2009/059531 WO2010012651A2 (en) 2008-07-31 2009-07-24 Composition useful for the prevention or reduction of the progression of prostate cancer

Publications (1)

Publication Number Publication Date
DK2310023T3 true DK2310023T3 (da) 2016-12-12

Family

ID=39967972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09781009.7T DK2310023T3 (da) 2008-07-31 2009-07-24 Sammensætning, som omfatter ekstrakt af grøn te og ekstrakt af granatæble til anvendelse ved forebyggelse eller reduktion af progression af prostatacancer

Country Status (20)

Country Link
US (2) US8758835B2 (da)
EP (1) EP2310023B1 (da)
JP (1) JP5564499B2 (da)
KR (1) KR101621910B1 (da)
CN (1) CN102112141B (da)
AU (1) AU2009276035B2 (da)
BR (1) BRPI0916435A8 (da)
CA (1) CA2732205C (da)
DK (1) DK2310023T3 (da)
EA (1) EA019814B1 (da)
ES (1) ES2602834T3 (da)
HK (1) HK1158076A1 (da)
HR (1) HRP20161447T1 (da)
HU (1) HUE031821T2 (da)
MX (1) MX2011000941A (da)
MY (1) MY160546A (da)
PL (1) PL2310023T3 (da)
PT (1) PT2310023T (da)
SG (2) SG10201700334XA (da)
WO (1) WO2010012651A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2982460B1 (fr) * 2011-11-14 2016-08-05 Virbac Sa Produits pour administration orale comprenant des extraits de grenade punica granatum, destines a un animal de compagnie, et ses applications
CN102652778A (zh) * 2012-03-29 2012-09-05 武汉华大药业有限公司 药物组合物
CN105796803A (zh) * 2014-12-30 2016-07-27 青岛加云华海健康科技有限公司 一种治疗和预防前列腺疾病的中药组合物及其制备和应用
CN108451979B (zh) * 2018-06-28 2020-04-28 新疆金骏阳光生物科技有限公司 一种具有辅助治疗前列腺癌的番茄红素复方制剂及其应用
KR102514074B1 (ko) 2022-08-10 2023-03-27 (주)스마트푸릇 체내흡수율이 증가된 엘라그산과 갈산을 고함량 포함하는 혈관건강, 전립선 또는 성기능 개선용 석류 발효조성물 및 efc 공법을 이용한 그의 제조방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030622A (en) * 1998-06-23 2000-02-29 Shehadeh; Ahmad Abdallah Herbal extract composition and method with immune-boosting capability
US20030086986A1 (en) * 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
FR2791573B1 (fr) * 1999-03-30 2003-04-11 Pf Medicament Utilisation d'un extrait de serenoa repens pour la fabrication d'un medicament destine au traitement du cancer de la prostate
US6818234B1 (en) * 1999-08-27 2004-11-16 Access Business Group International Llc Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation
DE20009840U1 (de) * 2000-05-31 2000-08-24 Phyt-Immun GmbH, 66424 Homburg Nahrungsergänzungsmittel, Arzneimittel oder Arzneimittelbestandteil, jeweils enthaltend ein Schalotten/Öl-Mazerat
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
US8337914B2 (en) * 2002-02-27 2012-12-25 Access Business Group International Llc Dietary food supplement containing natural cyclooxygenase inhibitors and methods for inhibiting pain and inflammation
JP2004035550A (ja) * 2002-05-07 2004-02-05 Access Business Group Internatl Llc 植物栄養素栄養サプリメント
US6572899B1 (en) * 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
US20060251750A1 (en) * 2002-09-30 2006-11-09 Tabor Aaron T Soy formulations and their use in skin care
US8357945B2 (en) * 2002-12-27 2013-01-22 Momentive Performance Materials Inc. Gallium nitride crystal and method of making same
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
US20080038369A1 (en) * 2003-12-11 2008-02-14 Clark Ross G Methods And Compositions For The Treatment Of Prolactin-Receptor Related Disorders
WO2005095959A2 (en) * 2004-03-29 2005-10-13 Howard Murad Methods for treating dermatological conditions in a patient
US20060024385A1 (en) * 2004-07-27 2006-02-02 Pedersen Mark A Metabolic capacity enhancing compositions and methods for use in a mammal
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
CA2603863A1 (en) * 2005-04-07 2006-10-19 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
DE202005020103U1 (de) * 2005-12-23 2006-04-27 China Vital Med E.K. Nahrungsergänzungsmittel
US20080031979A1 (en) * 2006-08-04 2008-02-07 Claude Saliou Use of extracts for the treatment of viral disorders
EP2415469A1 (en) * 2006-10-24 2012-02-08 David W. Krempin Anti-Resorptive and Bone Building Dietary Supplements and Methods of Use
US7927633B2 (en) * 2008-03-28 2011-04-19 Janiece Diane Swilling Adaptogenic tea

Also Published As

Publication number Publication date
US20110262417A1 (en) 2011-10-27
CA2732205C (en) 2018-01-02
MY160546A (en) 2017-03-15
SG192527A1 (en) 2013-08-30
PL2310023T3 (pl) 2017-02-28
MX2011000941A (es) 2011-03-29
KR20110043615A (ko) 2011-04-27
BRPI0916435A8 (pt) 2017-12-26
ES2602834T3 (es) 2017-02-22
KR101621910B1 (ko) 2016-05-17
EP2310023A2 (en) 2011-04-20
WO2010012651A2 (en) 2010-02-04
HRP20161447T1 (hr) 2016-12-16
AU2009276035A1 (en) 2010-02-04
US8758835B2 (en) 2014-06-24
BRPI0916435A2 (pt) 2016-02-16
HK1158076A1 (en) 2012-07-13
WO2010012651A3 (en) 2010-04-01
SG10201700334XA (en) 2017-03-30
HUE031821T2 (en) 2017-08-28
EA201170269A1 (ru) 2011-06-30
CN102112141B (zh) 2013-03-06
US9084812B2 (en) 2015-07-21
PT2310023T (pt) 2016-11-22
EP2310023B1 (en) 2016-10-12
CN102112141A (zh) 2011-06-29
AU2009276035B2 (en) 2015-10-01
US20140255512A1 (en) 2014-09-11
EA019814B1 (ru) 2014-06-30
JP5564499B2 (ja) 2014-07-30
CA2732205A1 (en) 2010-02-04
JP2011529465A (ja) 2011-12-08

Similar Documents

Publication Publication Date Title
Ming et al. Effects of emodin and vitamin C on growth performance, biochemical parameters and two HSP70s mRNA expression of Wuchang bream (Megalobrama amblycephala Yih) under high temperature stress
Zheng et al. Effects of Oridonin on growth performance and oxidative stress in broilers challenged with lipopolysaccharide
Oršolić et al. Effects of local administration of propolis and its polyphenolic compounds on tumor formation and growth
US20090047371A1 (en) Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
Hodges et al. CoQ_ {10}: could it have a role in cancer management?
US9084812B2 (en) Composition useful for the prevention or reduction of the progression of prostate cancer
LAPIS et al. Effect of Avemar and Avemar+ Vitamin С on tumor growth and metastasis in experimental animals
US20080085330A1 (en) Compounds for stimulating stem cell proliferation including spirulina
CN101068558A (zh) 改良抗癌治疗
CN102600203A (zh) 用于氧化应激引起的退行性疾病预防或治疗的药物组合物
CN116271057A (zh) 一种预防或治疗滤泡淋巴瘤的联合用药物组合物及其应用
US20080089905A1 (en) COMPOUNDS FOR STIMULATING STEM CELL PROLIFERATION INCLUDING AFA-OMEGA (EtOH)
Konno Effect of various natural products on growth of bladder cancer cells: two promising mushroom extracts
KR102576410B1 (ko) 바실러스 균주와 5-fu를 유효성분으로 하는 대장암 치료용 약학 조성물
KR101282728B1 (ko) 꿩의 다리 추출물을 유효성분으로 하는 골 질환 예방 및 치료용 조성물
KR102147239B1 (ko) 근육 보호에 있어서 포리아 코코스 추출물 및 투물로스산의 용도
KR20040097446A (ko) 화살나무 수용성 추출물 및 이의 용도
JP2022186421A (ja) ベージュ脂肪細胞分化誘導促進剤
AU2013319784A1 (en) Halobacteria extracts composition for tumor reduction
KR20120068606A (ko) 개면마 추출물을 유효성분으로 하는 골 질환 예방 및 치료용 조성물
HIDvÉGII et al. ANTTINTERESENTI
EP2821107A1 (en) Composition and use thereof for the treatment of benign and malign diseases
KR20000022334A (ko) 렉틴 조성물 및 이의 용도
Al-Ahmadi Effect of Usnic Acid (UA) and Conjugated Linoleic Acid (CLA) on Adiposity and BodWeight of Ratsies
CA2458805A1 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer